MedLife stock posts RON 10.9800 on BVB with 16,965 shares traded

Published on 10/08/2026 at 03:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MedLife stock's H1 2026 pro forma revenue rose 10.7 percent to RON 1.74 billion. EBITDA reached RON 258.9 million, while net loss was RON 20.4 million.

MedLife, ROMEDLACNOR6, Illustration mit AI erstellt.

MedLife (ISIN ROMEDLACNOR6) was last at RON 10.9800 on the Bucharest Stock Exchange on October 7, 2026, with 16,965 shares traded and a daily change of -0.18 percent. The latest operating figures give that price report its business context, even as the H1 release has already been reflected in recent coverage.

Revenue grew in H1 2026

According to MedLife in its September 2026 presentation, pro forma revenue reached RON 1.74 billion in the first half of 2026, up 10.7 percent from the same period of 2025. Pro forma EBITDA rose 14.5 percent to RON 258.9 million, lifting the EBITDA margin to 16.4 percent from 14.4 percent.

The comparison is strongest in operations. Clinics revenue increased 15.1 percent to RON 674.99 million, laboratory revenue rose 12.6 percent to RON 194.56 million, and corporate revenue gained 16.9 percent to RON 175.64 million in H1 2026, according to the same MedLife presentation.

Loss and leverage remain relevant

The profit picture was weaker than the operating trend. MedLife posted a pro forma net loss of RON 20.4 million for H1 2026, while a one-off litigation expense of EUR 1.5 million and a 2.8 percent depreciation of the Romanian leu against the euro weighed on the result, the company said in its presentation.

Net debt reached RON 1.865 billion on June 30, 2026, and the net debt-to-pro forma EBITDA ratio stood at 3.85x. MedLife's stated objective is to reduce that ratio toward 3.5x by the end of 2026, making deleveraging a central counterweight to the revenue and margin gains.

Consensus target stays near the price

The published analyst consensus was Neutral, based on 4 analysts, with 1 Buy, 4 Hold and 0 Sell recommendations. The average 12-month price target was RON 10.89, with a high estimate of RON 12.50 and a low estimate of RON 7.10, according to Investing.com.

MedLife's RON 10.9800 price on October 7 was 0.18 percent below the prior session level. The stock remains included in the BET index, alongside 19 other companies listed on the BVB, according to BVB.

MedLife stock stays below its yearly high

MedLife stock was last at RON 10.9800 on the BVB on October 7, 2026. Its 52-week range was RON 7.75 to RON 14.46, while market capitalization stood at RON 5.52 billion on September 29, 2026.